KYMR
Kymera Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$111.06-4.07%
Price as of Jul 20, 2026
KYMR growth
Kymera Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -12.6%
- EBITDA
- -31.5%
- EBIT
- -29.1%
- EPS
- -15.5%
- Free cash flow
- -1.7%
- Operating cash flow
- -3.6%
Forward estimates
- Revenue
- -15.7%
- EBITDA
- +85.8%
- EPS
- +5.3%
Three-year CAGR
- Revenue
- -5.8%
- EBITDA
- -40.2%
- EBIT
- -33.5%
- Net income
- -39.1%
- EPS
- -23.8%
- Free cash flow
- -13.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.